LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
LEXICON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.55+0.03 (+1.97%)
Close on Oct 19, 2026
- Market cap
- $678.36M
- P/E (TTM)
- –
- Dividend yield
- –
LEXICON PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| License | $45.00M | $25.00M | $0 | – | 90.4% | +80.0% |
| Product | $4.65M | $6.00M | $1.11M | – | 9.3% | -22.6% |
By region
From the segment and revenue-disaggregation notes of Lexicon Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.